T1EV34 trade ideas
TEVA is a great downtrend and Gives a selling opportunity.Sell Teva now. We are in a downtrend and the price gives us a good opportunity to sell
OPENING: TEVA MARCH 15TH 15/19/19/23 IRON FLY... for a 2.00/contract credit.
Metrics:
Max Profit: $200
Max Loss: $200
Break Evens: 17.00/21.00
Theta: 2.05
Delta: -3.92
Notes: A classic risk one to make one iron fly. Will look to take profit at 25% max.
THE WEEK AHEAD: TEVA, BIDU, RIG, XOPBIDU (44/42), RIG (33/56), and TEVA (49/53) announce earnings this week, with TEVA looking for a March to April volatility contraction of about 15%, BIDU, approximately 7.7%, and RIG, 6.9%. Instead of looking to play these pre-announcement for a volatility contraction (the contraction percentages aren't that compelling), I'll look to potentially short put/acquire/cover instead,* particularly since all of these underlyings have been hammered of late and are at the low end of their 52-week ranges.
Pictured here is a Plain Jane, TEVA 20-ish delta 16 short put in the April expiry; it's paying .51 with a break even of 15.49. The more aggressive 30 would be at the 17 strike and is currently paying .79 with a 16.21 break even. On margin, the 16 short ties up about 320 to put on, the 17, 340, with respective returns on capital of 16% and 23% at max. The break evens represent a 15% discount over current price for the 16 short put; an 11% discount for the 17.
The BIDU April 18th 155 (25 delta) is paying a 4.55 credit with a break even of 150.45, a potential 14.7% return on capital at max and a 11.4% discount over current price if assigned. As with TEVA, there is little point in holding shares if you don't have to, since it does not pay a divvy. If you end up in-the-money, roll as is and proceed to sell calls against to reduce cost basis.
If you're not into tying up 31.00 in buying power on Baidu, there is RIG. Unfortunately, due to its size, you're going to have to go closer to the money to make it worthwhile in dollar and cents terms: the April 15th 8 short put (40 delta) is paying .57 with a break even of 7.43 -- a 35.6% potential return on capital at max and a 10.3% discount over current price if assigned.
On the exchange-traded fund front, not much is hopping from a premium selling standpoint with VIX dropping into the 15's from its 2018 year-end highs of 36+, so I'll be looking to hand sit and keep powder dry for a higher volatility environment to get into nondirectional setups in broad market instruments. That being said, I will continue to sell premium in XOP, where the 30-day implied is over twice that of the broader market (34.1% versus SPY 15%).
* -- The natural alternative should you not be interested in acquiring shares would be to roll the short put out in time "as is" if it hasn't worked out and then proceed to cover with a short call. The last two dividends were a paltry .07, so I could see not wanting to tie up buying power to be in the shares unless you absolutely have to.
Long $TEVA Pharmaceutical StockTEVA develops, manufactures and sells generic medicine in a range of forms including tablets, capsules, injectables, inhalants, liquids, ointments and creams. They also create specific speciality medicines that assist the Central Nervous System and Respiratory medicines focused on asthma and chronic obstructive pulmonary disease. One of their primary drugs is Copaxone.. used to treat multiple sclerosis however we are seeing more and more generic competition come into the marketplace.
Teva Investor FAQ: ir.tevapharm.com
See past analysis for more insight on what happened when it was publically disclosed that Warren Buffet increased his stake to owning 4.25% of the entire companies stock.
Pros:
Cheap/Mid Range Stock Price
Wealthy Investment Firms Are Positioned
Longstanding Global Brand
Cons
Pharma Sector Competition
No more dividends paid to holders as of this time
At risk of further bearish movement if the stock market falls due to overvaluation on major indexes
Trading can contain substantial risk and is not suited for every investor. An investor could potentially lose all or more than their initial investment. "Risk capital" - is money that can be lost without jeopardizing ones financial security or life style. Only "risk capital" should be used for trading and only those with sufficient risk capital should consider trading. I am not a licensed financial advisor nor do I give out financial advice. You assumes full risk and responsibility for their trading activity. Past performance is not indicative of future results. Individual results will vary due to a variety of market and timing conditions.
TEVA on the 4-HrI am long TEVA and feel we are a bit over-extended on price action North and hoping for a pullback to $17.80 or lower to get more (If not, oh well). I have a $21.00 price target (3-weeks) timeframe. Let's see if there is some profit taking to bring the price action down to the level mentioned.
This analysis speaks for itself -- the chart display's a V-Bottom on the 4-Hr and the stock has taken a beating. Warren Buffet took a position in this company just before it fell, so I will follow the money!
Good Luck,
Biff
$TEVAAscending traingle but no volume, very suspicious. Would usually long this set up but will wait for confirmation and volume income.
$TEVABear flag seems about to break downwards. I would aim that order block (green box) for a conservative target.
Target 2 is possible but may take a little longer.
Low volume PullbackI see a low volume pullback here, it is possible price wont be able to close above the support/Resistance level.
Teva to 30$ TEVA was saved by the 50 weeks MA line.
The stock is now back above a weekly uptrend line.
If it will hold above it and close above it... chances are that we will see TEVA advancing towards 30$
Teva possible break-outToday is possible that Teva may break the upside line of the descending channel as drawn in the picture. In this case, first TP1 is fixed at 25.14 dollars, TP2 at 27,74.
A Technical Analysis Look at TEVA Stock Any TEVA stock price falling on or below the hypothesized mean of $22.00, will signal the initiation of a buy order. On the other hand, any price rising above the hypothesized mean of $22.00 or within the range of $22.00 to $23.26 and above, will signal the initiation of a sell order. As of writing this Technical Indicator article, (November 5, 2018) the price of TEVA hit a low of $21.98, which is well within our target range of initiating a buy order.
Therefore, if we had bought the stock at our hypothesized buy range of $22.00 or below, we would have made a nice profit of $0.85 (cents) per share because the stock closed at a $22.85 per share, a change of $0.26 (cents) per share, which is a 1.15% change for the day (November 5, 2018).
Not only that, an early morning trade right after the market opened at 9:45 am would have given us a nice gain of $1.26 per share if we had followed our Mstardom Finance trading strategy of closing our long position or shorting the stock when it got to our range’s upper limit garget of $23.26.
As soon as the price hit our $23.26 target, we would’ve had to exit the trade because in trading, greed causes traders to lose money, so as wise traders, we would’ve exited the trade several minutes before the stock got to its high point of $23.34. The Mstardom Finance community doesn’t care about a few extra pennies when we already got a sizable gain in our basket.
The good thing is that this Mstardom Finance Trading Strategy is still relevant at the present time and in the not-so-distant future, once the hypothesized mean and the character of the TEVA stock stays the same.
We are able to deduce such optimism because the stock has a very low volatility characteristic, based on our analytical assessment lend to us by our proprietary strategy.
All we at Mstardom Finance cares about is helping the retail trader make money. So, when you hop over to Mstardom Finance, you will see articles, posts, and trading tools that provide the little retail trader with resources and information that will help him or her compete with the institutional or professional trader. This is what our upcoming trading book will be about, preventing the retail trader from being victims of the financial markets.
Please click here to read the rest of the article, which includes a look at TEVA Fundamentals and how it has affected the movement of the stock
Disclosure: (R) Mstardom Finance, Mstardom Finance does not provide investment advise.
Teva finishing accumulation stage.Price under but close to Volume profile (POI). I think it is good time to open short position.
TEVA- I have a bad feeling about this oneIt already had a horrible reaction to Earnings. Sure looks like this is falling out of favor.
WARREN BUFFETT INCREASES STAKE IN TEVA TO 4.3%NEWS - 2 DAYS AGO
Billionaire investor Warren Buffett increased his stake in Teva Pharmaceutical Industries to 4.3% during the second quarter of 2018, according to the quarterly financial statement from his investments firm Berkshire Hathaway. ... Altogether its stake is worth $957 million, according to Teva's closing price on Tuesday.
TEVA HAS A STRONG PIPELINE OF NEW DRUGS COMING TO MARKET
TEVA WINS FDA APPROVAL - EPIPEN FOR PEDIATRIC CHILDRENA MUST READ ARTICLE!!
The FDA Approval is "NOT" just for adults. FDA also gave TEVA approval to administer the EPIPEN to PEDIATRIC CHILDREN
arstechnica.com
Pediatric Sub-population
Approximate Age Range
Newborn - birth to 1 month of age
Infant - 1 month to 2 years of age
Child - 2 to 12 years of age
Adolescent - 12-21 years of age
This opens up a whole new Sales Market / Revenue Stream for TEVA and the Generic Epipen.
FOOD ALLERGY RESEARCH GROUP (FARE)
How Many People Have Food Allergies?
Researchers estimate that up to 15 million Americans have food allergies, including 5.9 million children under age 18. That’s 1 in 13 children, or roughly two in every classroom.
About 30 percent of children with food allergies are allergic to more than one food.
Food Allergies Are on the Rise
The Centers for Disease Control & Prevention reports that the prevalence of food allergy in children increased by 50 percent between 1997 and 2011.
Between 1997 and 2008, the prevalence of peanut or tree nut allergy appears to have more than tripled in U.S. children.
Possible bounce on $TEVAteva has pulled back now for 3 days, we can possibly have a bounce off the 50MA, if this turns out to b the case, then this would result in the 21MA crossing above the 50MA which signals a bullish move, manage risk. GLTA
Teva still positive but...$Teva is still positive in the uptrend although the candle of yesterday has turned some indicators in bearish position. Over the mid term bullish trend is still strong. Having said that next candles have to be monitored because on a monthly basis there is a potential dragon fly bearish, thus a prompt recover toward the upper edge of the bullish flag is important for further climb. I will keep the chart under observation in the next days.
